Pharvaris N.V.
NASDAQ:PHVSBiotechnology
-$0.64 today
- Market cap
- $2.21B
- Beta
- -2.33
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.59
Volume 0.39M
Average 0.31M
PHVS Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Pharvaris N.V.NASDAQ: PHVS
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses grows, but more slowly than its trailing trend
Q3 FY2026 other income / expenses of €2.88M rose 22.9% year over year, behind the +118.3% change in trailing-twelve-month other income / expenses. Sequentially, it fell 18.7% from the prior quarter.
Context
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +22.9% toward the trailing-twelve-month pace of +118.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
EUR · from the income statement
- Latest · FY2025
- (3.89M) EUR
- Year-over-year change
- -129.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.89M) | -129.3% |
| FY2024 | 2024-12-31 | 13.29M | +556.4% |
| FY2023 | 2023-12-31 | (2.91M) | -126.3% |
| FY2022 | 2022-12-31 | 11.06M | -3.6% |
| FY2021 | 2021-12-31 | 11.48M | — |
Other Income / Expenses vs competitors
How PHVS compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +118.3% is the 2nd highest of 7, against a peer median of -1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.31M USD | +825.7% | +149.4% | 2367.1% | |
| LTM Sep 2026 | €14.39M EUR | +118.3% | — | — | |
| LTM Jun 2026 | $13.87M USD | -22.0% | +104.7% | — | |
| LTM Mar 2026 | -$3.5M USD | +18.6% | — | 0.9% | |
| LTM Sep 2026 | -$26.23M USD | -1115.7% | — | 4.0% | |
| LTM Jun 2026 | -$68.03M USD | +21.3% | — | 7.2% | |
| LTM Sep 2026 | -$49.83B USD | -78235.6% | — | 4.9% | |
| Peer median (excluding PHVS) | — | -1.7% | +127.1% | 4.9% | |
Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.79M | 57.38M | 65.58M | 98.56M | 124.48M |
| Selling, General & Admin | 18.35M | 29.34M | 31.34M | 47.12M | 45.34M |
| Operating Expenses | 54.14M | 86.71M | 96.91M | 145.69M | 169.82M |
| Depreciation & Amortization | 77.37K | 152.94K | 257.55K | 269.56K | 418.35K |
| EBITDA | (42.31M) | (86.56M) | (99.57M) | (145.42M) | (173.29M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (54.14M) | (86.71M) | (96.91M) | (145.69M) | (169.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 268 | 16 | 0 | 5.47M | 0 |
| Interest Expense | 278.18K | 16.11K | 0 | 0 | 0 |
| Other Income / Expenses | 11.48M | 11.06M | (2.91M) | 13.29M | (3.89M) |
| Income Before Tax | (42.66M) | (75.65M) | (99.83M) | (132.4M) | (173.71M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 70.12K | 679.09K | 1.05M | 1.83M | 1.99M |
| Net Income | (42.73M) | (76.33M) | (100.88M) | (134.22M) | (175.7M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.41) | (2.27) | (2.63) | (2.48) | (2.97) |
| EPS (Diluted) | (1.41) | (2.27) | (2.63) | (2.48) | (2.97) |
| Weighted Avg Shares | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M |
| Weighted Avg Shares (Diluted) | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M |
Pharvaris N.V.
NASDAQ:PHVS
Intrinsic Alpha fair value
Locked
Current Price
$31.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.